These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1457 related articles for article (PubMed ID: 33976287)

  • 1. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease.
    AlQahtani M; Abdulrahman A; Almadani A; Alali SY; Al Zamrooni AM; Hejab AH; Conroy RM; Wasif P; Otoom S; Atkin SL; Abduljalil M
    Sci Rep; 2021 May; 11(1):9927. PubMed ID: 33976287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.
    Balcells ME; Rojas L; Le Corre N; Martínez-Valdebenito C; Ceballos ME; Ferrés M; Chang M; Vizcaya C; Mondaca S; Huete Á; Castro R; Sarmiento M; Villarroel L; Pizarro A; Ross P; Santander J; Lara B; Ferrada M; Vargas-Salas S; Beltrán-Pavez C; Soto-Rifo R; Valiente-Echeverría F; Caglevic C; Mahave M; Selman C; Gazitúa R; Briones JL; Villarroel-Espindola F; Balmaceda C; Espinoza MA; Pereira J; Nervi B
    PLoS Med; 2021 Mar; 18(3):e1003415. PubMed ID: 33657114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial.
    Diago-Sempere E; Bueno JL; Sancho-López A; Rubio EM; Torres F; de Molina RM; Fernández-Cruz A; de Diego IS; Velasco-Iglesias A; Payares-Herrera C; Flecha IC; Avendaño-Solà C; Palomino RD; Ramos-Martínez A; Ruiz-Antorán B
    Trials; 2021 Jan; 22(1):70. PubMed ID: 33472681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
    Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
    Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
    Devos T; Geukens T; Schauwvlieghe A; Ariën KK; Barbezange C; Cleeren M; Compernolle V; Dauby N; Desmecht D; Grimaldi D; Lambrecht BN; Luyten A; Maes P; Moutschen M; Romano M; Seyler L; Nevessignsky MT; Vandenberghe K; van Griensven J; Verbeke G; Vlieghe E; Yombi JC; Liesenborghs L; Verhamme P; Meyfroidt G
    Trials; 2020 Nov; 21(1):981. PubMed ID: 33246499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Menichetti F; Popoli P; Puopolo M; Spila Alegiani S; Tiseo G; Bartoloni A; De Socio GV; Luchi S; Blanc P; Puoti M; Toschi E; Massari M; Palmisano L; Marano G; Chiamenti M; Martinelli L; Franchi S; Pallotto C; Suardi LR; Luciani Pasqua B; Merli M; Fabiani P; Bertolucci L; Borchi B; Modica S; Moneta S; Marchetti G; d'Arminio Monforte A; Stoppini L; Ferracchiato N; Piconi S; Fabbri C; Beccastrini E; Saccardi R; Giacometti A; Esperti S; Pierotti P; Bernini L; Bianco C; Benedetti S; Lanzi A; Bonfanti P; Massari M; Sani S; Saracino A; Castagna A; Trabace L; Lanza M; Focosi D; Mazzoni A; Pistello M; Falcone M;
    JAMA Netw Open; 2021 Nov; 4(11):e2136246. PubMed ID: 34842924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2021 May; 397(10289):2049-2059. PubMed ID: 34000257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial).
    van den Berg K; Glatt TN; Vermeulen M; Little F; Swanevelder R; Barrett C; Court R; Bremer M; Nyoni C; Swarts A; Mmenu C; Crede T; Kritzinger G; Naude J; Szymanski P; Cowley J; Moyo-Gwete T; Moore PL; Black J; Singh J; Bhiman JN; Baijnath P; Mody P; Malherbe J; Potgieter S; van Vuuren C; Maasdorp S; Wilkinson RJ; Louw VJ; Wasserman S
    Sci Rep; 2022 Feb; 12(1):2552. PubMed ID: 35169169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Assessing Convalescent Plasma Efficacy in Moderate COVID-19 Hospitalizations: A Bicentric Retrospective Study].
    Torres V; Olivares F; Fernández C; Calvo M; Orellana C; Navarrete M; Lesina B; Fuentes M; Blackburn E; Velásquez G; Vera A; Rojas-Fernández A; Himelreichs J
    Rev Med Chil; 2023 Jun; 151(6):717-724. PubMed ID: 38801380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study.
    Rojas M; Rodríguez Y; Hernández JC; Díaz-Coronado JC; Vergara JAD; Vélez VP; Mancilla JP; Araujo I; Yepes JT; Ricaurte OB; Pardo-Oviedo JM; Monsalve DM; Acosta-Ampudia Y; Ramírez-Santana C; García PG; Landinez LA; Correales LD; Grass JS; Pérez CR; López GS; Mateus N; Mancera L; Devia RR; Orjuela JE; Parra-Moreno CR; Buitrago AA; Ordoñez IE; Osorio CF; Ballesteros N; Patiño LH; Castañeda S; Muñoz M; Ramírez JD; Bastard P; Gervais A; Bizien L; Casanova JL; Camacho B; Gallo JE; Gómez O; Rojas-Villarraga A; Pérez CE; Manrique R; Mantilla RD; Anaya JM
    BMC Infect Dis; 2022 Jun; 22(1):575. PubMed ID: 35761219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia.
    Avendaño-Solá C; Ramos-Martínez A; Muñez-Rubio E; Ruiz-Antorán B; Malo de Molina R; Torres F; Fernández-Cruz A; Calderón-Parra J; Payares-Herrera C; Díaz de Santiago A; Romera-Martínez I; Pintos I; Lora-Tamayo J; Mancheño-Losa M; Paciello ML; Martínez-González AL; Vidán-Estévez J; Nuñez-Orantos MJ; Saez-Serrano MI; Porras-Leal ML; Jarilla-Fernández MC; Villares P; de Oteyza JP; Ramos-Garrido A; Blanco L; Madrigal-Sánchez ME; Rubio-Batllés M; Velasco-Iglesias A; Paño-Pardo JR; Moreno-Chulilla JA; Muñiz-Díaz E; Casas-Flecha I; Pérez-Olmeda M; García-Pérez J; Alcamí J; Bueno JL; Duarte RF;
    J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34473652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convalescent Plasma for Patients Hospitalized With Coronavirus Disease 2019: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials.
    Ling RR; Sim JJL; Tan FL; Tai BC; Syn N; Mucheli SS; Fan BE; Mitra S; Ramanathan K
    Transfus Med Rev; 2022 Jan; 36(1):16-26. PubMed ID: 34782209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of convalescent plasma transfusion for the treatment of severely ill COVID-19 patients in Pakistan.
    Khan TNS; Mukry SN; Masood S; Meraj L; Devrajani BR; Akram J; Fatima N; Maqsood S; Mahesar A; Siddiqui R; Ishaque S; Afzal MB; Mukhtar S; Ahmed S; Naz A; Shamsi TS
    BMC Infect Dis; 2021 Sep; 21(1):1014. PubMed ID: 34579646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma.
    Gemici A; Bilgen H; Erdoğan C; Kansu A; Olmuşçelik O; Beköz HS; Çakmak R; Mert A; Sevindik ÖG
    Turk J Med Sci; 2020 Dec; 50(8):1781-1785. PubMed ID: 33078604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol.
    Misset B; Hoste E; Donneau AF; Grimaldi D; Meyfroidt G; Moutschen M; Compernolle V; Gothot A; Desmecht D; Garigliany M; Najdovski T; Laterre PF
    BMC Pulm Med; 2020 Dec; 20(1):317. PubMed ID: 33287790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.